AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics by its i-body platform in Australia. Its lead product is AD-214, an antibody therapeutic, which is in Phase I clinical trial for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis and interstitial lung disease, kidney fibrosis, eye fibrosis, and various cancers. AdAlta Limited has collaborative partnerships with GE Healthcare to develop i-body enabled granzyme B PET imaging agents for use in immuno-oncology; and Carina Biotech to develop CAR-T cell products against various solid tumor antigens. The company was incorporated in 2006 and is based in Bundoora, Australia.
| Market Capitalization | $9.2989 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.005 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.02 |
| EBITDA | -4,841.327 |
| Profit Margin | -1.3984 |
| Operating Margin TTM | -1.4041 |
| Return on Assets TTM | -0.3313 |
| Return on Equity TTM | -1.3312 |
| Revenue TTM | 3,469.179 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2012-06-30 | 561 | 657 | ||
| 2013-06-30 | 813 | 1,203 | ||
| 2014-06-30 | 744.736 | 1,610.148 | -865.412 | 1,993.568 |
| 2015-06-30 | 887.927 | 1,795.917 | -907.99 | 2,208.623 |
| 2016-06-30 | 746.95 | 1,413.98 | -667.03 | 1,910.004 |
| 2017-06-30 | 1,967.68 | 3,598.678 | -3,598.678 | 1,201.519 |
| 2018-06-30 | 2,079.98 | 3,980.633 | -3,980.633 | 1,901.483 |
| 2019-06-30 | 615.819 | 7,353.66 | -6,737.841 | 2,174.195 |
| 2020-06-30 | 3,846.88 | 7,012.24 | -6,396.421 | 2,655.345 |
| 2021-06-30 | 3,987.316 | 848.19 | 9,402.67 | |
| 2022-06-30 | 2,755.223 | 987.936 | 8,752.522 | |
| 2023-06-30 | 3,531.75 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2012-06-30 | 1,189 | 1,212 | 178 | 2,490 | ||
| 2013-06-30 | 575 | 608 | 335 | 2,490 | ||
| 2014-06-30 | 382.302 | 459.763 | 286.947 | 2,490.279 | ||
| 2015-06-30 | 34.864 | 967.071 | 261.181 | 2,490.279 | ||
| 2016-06-30 | 10,710.53 | 10,729.871 | 114.13 | 17,676.331 | ||
| 2017-06-30 | 6,224.617 | 8,089.89 | 344.512 | 0 | 17,560.338 | |
| 2018-06-30 | 2,306.048 | 4,438.948 | 366.317 | 0 | 17,573.527 | |
| 2019-06-30 | 5,555.875 | 9,310.021 | 1,818.912 | 2,191.327 | 26,809.501 | |
| 2020-06-30 | 3,366.503 | 6,907.46 | 3,205.374 | 2,191.327 | 28,436.476 | |
| 2021-06-30 | 5,791.389 | 9,049.382 | 2,663.032 | 1,687.491 | 36,232.03 | |
| 2022-06-30 | 8,738.474 | 10,648.546 | 5,270.034 | 2,389.567 | 1,613.386 | 41,010.888 |
| 2023-06-30 | 4,961.954 | 7,733.089 | 5,823.135 | 4,013.858 | 0 | 42,175.065 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2012-06-30 | ||||||
| 2013-06-30 | ||||||
| 2014-06-30 | -1,248.832 | -1,290.048 | -192.703 | |||
| 2015-06-30 | -1,307.868 | -1,382.438 | -347.438 | |||
| 2016-06-30 | -1,163.056 | -1,174.36 | 450.69 | 485.558 | ||
| 2017-06-30 | -2,832.517 | -3,726.823 | 5,739.059 | 485.558 | 6,224.617 | |
| 2018-06-30 | -3,854.894 | -3,928.616 | -3,918.569 | 6,224.617 | 2,306.048 | |
| 2019-06-30 | -2,308.531 | -5,816.085 | 3,249.827 | 2,306.048 | 5,555.875 | |
| 2020-06-30 | -6,122.002 | -5,903.881 | -2,189.372 | 5,555.875 | 3,366.503 | 2,284.363 |
| 2021-06-30 | -5,725.993 | -4,781.742 | 2,424.886 | 3,366.503 | 5,791.389 | |
| 2022-06-30 | -6,172.402 | -6,139.29 | 2,869.167 | 5,791.389 | 8,660.556 | |
| 2023-06-30 | -4,851.187 | -5,132.058 | -3,871.043 | 8,660.556 | 4,789.513 |